Please ensure Javascript is enabled for purposes of website accessibility

Today's After-Hours News: Allergan and American Eagle Are Trading Lower

By Daniel Sparks - Updated Apr 11, 2019 at 3:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing phase 3 drug results and a weaker-than-expected revenue outlook are weighing on these stocks.

Stocks of pharmaceutical-company Allergan (AGN) and apparel-retailer American Eagle Outfitters (AEO 0.91%) are trading lower after market close on Wednesday. Allergan shared disappointing news about one of its drugs in development, and American Eagle's first-quarter guidance was underwhelming, despite a strong fourth quarter.

Here's a closer look at both of these stories.

A group of stylishly-dressed young people.

Image source: Getty Images.

American Eagle Outfitters

Apparel-retailer American Eagle Outfitters posted notable fourth-quarter results, but may have let some investors down when it came to its first-quarter earnings-per-share (EPS) guidance.

Revenue rose 1% year over year to a record $1.24 billion, even though there was one less week than in the year-ago quarter. Revenue would have been about $60 million higher in the quarter if the period had an additional week, management said. Comparable sales increased 6% year over year -- on top of an 8% increase in the year-ago quarter.

Management expects comparable-sales growth to slow in Q1, rising at a percentage rate in the low single digits. In addition, American Eagle guided for first-quarter EPS between $0.19 and $0.21. Analysts, on average, were expecting first-quarter EPS of $0.24.

"Strong execution by the teams drove a record fourth quarter and fiscal 2018, as we reached a milestone of $4 billion in annual revenue with increased operating profit," said American Eagle CEO Jay Schottenstein in the company's fourth-quarter earnings release. "American Eagle and Aerie continued to deliver consistent performance by combining product innovation and great merchandise with an improved customer experience across channels."

Looking to 2019, management says the company's strong balance sheet and free cash flow allows it to "make important investments in our business to fuel market share gains, future growth and returns to our shareholders."

Shares of American Eagle were down about 3.1% in after-hours trading as of 5:50 p.m. EST.

Check out the latest earnings call transcripts for Allergan and American Eagle Outfitters.

Allergan

Also after market close on Wednesday, Dublin-based pharmaceutical leader Allergan announced disappointing results from phase 3 results for its rapastinel drug, which was aimed to be an adjunctive treatment of Major Depressive Disorder (MDD). The rapastinel treatment failed three acute studies as part of phase 3 adjunctive MDD trials.

"We are deeply disappointed with these results, and they are a vivid reminder that drug development is extremely challenging, especially in mental health," said Allergan's chief of research and development David Nicholson in the company's press release on Wednesday. 

The stock was down 3.5% in after-hours trading as of 5:50 p.m. EST.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

American Eagle Outfitters, Inc. Stock Quote
American Eagle Outfitters, Inc.
AEO
$14.35 (0.91%) $0.13
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.